Cyclic Nucleotide Phosphodiesterases, Type 4
"Cyclic Nucleotide Phosphodiesterases, Type 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic nucleotide phosphodiesterase subfamily that is found predominantly in inflammatory cells and may play a role in the regulation of CELL-MEDIATED IMMUNITY. The enzyme family includes over twenty different variants that occur due to multiple ALTERNATIVE SPLICING of the mRNA of at least four different genes.
MeSH Number(s)
D08.811.277.352.640.150.400
D12.644.360.008.400
D12.776.476.008.400
Concept/Terms
Cyclic Nucleotide Phosphodiesterases, Type 4- Cyclic Nucleotide Phosphodiesterases, Type 4
- PDE4 Phosphodiesterases
- Phosphodiesterases, PDE4
- Type 4 Cyclic Nucleotide Phosphodiesterase
- Phosphodiesterase IV
- Phosphodiesterase-4
- Cyclic Nucleotide Phosphodiesterase PDE4 Family
- Phosphodiesterase 4
Below are MeSH descriptors whose meaning is more general than "Cyclic Nucleotide Phosphodiesterases, Type 4".
Below are MeSH descriptors whose meaning is more specific than "Cyclic Nucleotide Phosphodiesterases, Type 4".
This graph shows the total number of publications written about "Cyclic Nucleotide Phosphodiesterases, Type 4" by people in Harvard Catalyst Profiles by year, and whether "Cyclic Nucleotide Phosphodiesterases, Type 4" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2009 | 3 | 0 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 3 | 1 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 1 | 2 |
Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 4" by people in Profiles.
-
Fe(III)-catalyzed regioselective and faster synthesis of isocoumarins with 3-oxoalkyl moiety at C-4: Identification of new inhibitors of PDE4. Bioorg Chem. 2022 04; 121:105667.
-
Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases. Sci Transl Med. 2022 01 05; 14(626):eabf3917.
-
PdCl2-catalyzed synthesis of a new class of isocoumarin derivatives containing aminosulfonyl / aminocarboxamide moiety: First identification of a isocoumarin based PDE4 inhibitor. Eur J Med Chem. 2021 Oct 05; 221:113514.
-
Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression. Leukemia. 2021 07; 35(7):1990-2001.
-
Inhibition of phosphodiesterase IV enzyme improves locomotor and sensory complications of spinal cord injury via altering microglial activity: Introduction of Roflumilast as an alternative therapy. Int Immunopharmacol. 2020 Sep; 86:106743.
-
Discovery and Optimization of a-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia. J Med Chem. 2020 03 26; 63(6):3370-3380.
-
Hyperinsulinemia promotes heterologous desensitization of ß2 adrenergic receptor in airway smooth muscle in obesity. FASEB J. 2020 03; 34(3):3996-4008.
-
Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions. Acta Biomater. 2019 05; 90:350-361.
-
Phosphodiesterase-4 inhibition reduces ECLS-induced vascular permeability and improves microcirculation in a rodent model of extracorporeal resuscitation. Am J Physiol Heart Circ Physiol. 2019 03 01; 316(3):H751-H761.
-
Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis. J Manag Care Spec Pharm. 2018 Dec; 24(12):1210-1217.